Business Context and Reporting Period
This Form 8-K reports on the 2014 Annual Meeting of Stockholders held by Capricor Therapeutics, Inc. on November 4, 2014, at its principal executive offices in Beverly Hills, California. The filing details the voting results on five specific matters submitted to security holders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Based on the presence of 7,259,851 shares (of 11,703,774 entitled to vote), the following matters were approved:
- Director Elections: All nine nominees (Frank Litvack, Linda Marbán, David B. Musket, George W. Dunbar, Jr., Louis Manzo, Louis J. Grasmick, Earl M. Collier, Jr., Gregory W. Schafer, and Joshua Kazam) were elected to the Board of Directors. Each received over 6.2 million "For" votes.
- Auditor Ratification: Stockholders ratified the appointment of Rose, Snyder & Jacobs LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2014, with 7,245,955 "For" votes.
- Executive Compensation: A non-binding advisory vote to approve the compensation of named executive officers was approved with 6,213,719 "For" votes.
- Voting Frequency: Stockholders voted for a three-year frequency for future non-binding advisory votes on executive compensation (4,953,496 votes for "Three Years").
- Equity Plan: The 2012 Restated Equity Incentive Plan, as amended, was approved with 6,142,569 "For" votes.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. It notes that the Company will include a non-binding advisory vote on executive compensation in its proxy materials once every three years, in accordance with the voting results and Board recommendation. No specific risks or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the composition of the newly elected Board of Directors and their tenure until the 2015 annual meeting.
- Confirm the terms of the 2012 Restated Equity Incentive Plan as amended, which was approved by stockholders.
- Review the Company's upcoming proxy materials to ensure the executive compensation advisory vote is scheduled for a three-year cycle.
- Check subsequent filings (e.g., 10-K) for the financial performance of the fiscal year ending December 31, 2014, as this 8-K contains no financial data.